You are here
|Active Portfolio Companies|
4D Molecular Therapeutics
4D Molecular Therapeutics is a gene therapy company with a transformative discovery platform – Therapeutic Vector Evolution – that enables invention of optimized and proprietary AAV vectors, each specifically designed to deliver genes to specific cells and tissues in the body, allowing treatment of diseases with high unmet medical needs. The company is currently focused on rare diseases of the eye, heart, muscle and lung.
New York, NY
Accelerator New York is a leading life science investment vehicle supporting emerging biotechnology research. Accelerator will infuse strategic venture capital, entrepreneurial leadership, and critical product development capabilities into the New York City life science cluster. Accelerator NY is located at the Alexandria Center for Life Science in the heart of Manhattan’s East Side Medical Corridor.
Adapsyn applies proprietary algorithms and artificial intelligence to genomic and metabolomic data from microbes to find novel natural product drug candidates. The company has created a turnkey solution to drive the discovery of a diversified portfolio of drugs, thereby expediting the search for medicines that will better treat a wide spectrum of diseases.
AMRA is a medical technology company that analytically transforms MR images into precise body composition measurements using a cloud-based, computer aided service. These highly accurate measurements aid metabolic research and drug development in the challenging areas of obesity and its co-morbidities.
AnTolRx develops novel nanoparticle-based therapies to promote antigen-specific immune tolerance. These nanoparticles selectively target pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases like Type 1 Diabetes, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Multiple Sclerosis.
Aquinnah Pharmaceuticals is pursuing a novel hypothesis for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases by developing small molecule therapeutics that target persistent stress granules, a common pathology of neurodegeneration.
Arkuda Therapeutics is developing medicines to improve the lives of patients with neurological diseases.
Arrakis Therapeutics is pioneering the discovery of small-molecule medicines that directly bind and modify the biological function of RNA to treat disease. This new class of medicines, RNA-targeted small molecules (rSMs), will focus on new disease intervention points identified in the human transcriptome as well as valuable targets that are not accessible with today’s medicines.
Artios Pharma is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The company is building a pipeline of next-generation DDR programs to target hard to treat cancers.
Autifony is a UK-based biotechnology company, spun-out from GSK in 2011. The company is focused on the development of high value, novel medicines to treat serious diseases of the central nervous system.
San Diego, CA
BioAtla develops novel monoclonal antibody and cell-based immunotherapies with improved therapeutic index for the treatment of cancer. The company’s proprietary platforms include Conditionally Active Biologics and Comprehensive Integrated Antibody Optimization that enable biologics with more selective targeting of cancer tissue and improved manufacturability.
South San Francisco, CA
Biodesy is a life science instrumentation company that has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. The technology can be used to measure functional activation in a protein upon binding drugs or ligands, in real time and without the need for a crystal structure.
South San Francisco, CA
Blade Therapeutics is a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs, leveraging insights from its founder’s laboratory, Hal Dietz, M.D., at Johns Hopkins University School of Medicine. The company’s lead program is a small molecule inhibitor targeting an intracellular cysteine protease that has been shown to be associated with fibrosis across diverse indications. Blade anticipates entering the clinic with its lead candidate in mid-2018.
Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. The company is leveraging its differentiated endogenous nitrated fatty acid cell signaling technology platform, to focus on Focal Segmental Glomerulosclerosis (FSGS) and Pulmonary Arterial Hypertension (PAH). Complexa believes its approach has the ability to not only halt, but to reverse, disease related fibrosis. The Company’s lead product CXA-10 has completed human safety and proof of target engagement studies and is moving into Phase 2 trials.
IPO in 2019 (TK: CRTX)
South San Francisco, CA
Cortexyme is developing therapeutics based on a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. Because the pathogen is persistent and resistant to broad spectrum antibiotics, Cortexyme has developed small molecules to stop disease progression.
Cydan II, Inc.
Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well understood biology and proof-of-concept data in animal models from academia, industry and other sources. Data generated during a rigorous de-risking process will enable formation of stand-alone companies and strategic partnerships.
IPO in 2015 (TK: CTMX)
South San Francisco, CA
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue.
San Diego, CA
eFFECTOR is a clinical stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule drugs for treating cancer. The company’s investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR’s most advanced program focuses on the development of eFT508, which is in Phase 1 studies. Additional selective translation regulator programs are currently in discovery and development.
FKA Celladon IPO in 2014 (TK: EIGR)
Palo Alto, CA
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. The company’s pipeline includes Sarasar (lonafarnib) and Pegylated Interferon Lambda for Hepatitis Delta (Phase 2), Exendin (9-39) for Hypoglycemia (Phase 2) and Bestatin (ubeninmex) for pulmonary arterial hypertension and lymphedema (Phase 1).
La Jolla, CA
Epic Sciences is focused on developing novel diagnostics to improve and personalize the treatment and management of cancer. Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs).
G-Con designs and manufactures “PODs”, portable, self-contained cGMP facility modules that offer a cost-effective and flexible alternative to large, highly capitalized pharmaceutical manufacturing facilities with fixed equipment and limited flexibility.
Imara develops IMR-687, a preclinical phosphodiesterase-9 (PDE-9) inhibitor for sickle cell disease and other hemoglobinopathies. The company was granted exclusive global rights to Lundbeck's IMR687.
Ixchelsis Limited is an independent biotechnology company based in Discovery Park, Sandwich, UK. Ixchelsis plans to develop to proof-of-concept, IX-01, an investigational compound originally discovered at Pfizer’s R&D site in Sandwich, UK. IX-01 is an Oxytocin receptor antagonist with the potential to treat premature ejaculation, benign prostatic hypertrophy and prostate cancer.
Jnana Therapeutics is building the first small molecule drug discovery platform dedicated to SLC transporters, an ancient membrane protein family thought to be relevant in a wide range of diseases. Jnana’s proprietary chemistry and biology platform allows the company to rapidly and comprehensively address therapeutic targets across the SLC family, with an initial focus on immuno-oncology, inflammatory disorders, and neurological diseases.
Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases by advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Using its protein degradation platform, the company is building a therapeutic pipeline in oncology and immunology.
New York, NY
Lodo's genome-based, culture-independent platform combines DNA sequencing and bioinformatics to discover, synthesize, and characterize small-molecule therapeutics from natural microbial sources present in soil samples and the human microbiome. The company will initially focus on infectious diseases like tuberculosis, but also plans to pursue additional therapeutic areas including oncology, metabolic disorders, and rare diseases.
New York, NY
Mangolia Neurosciences is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. The company is focused on developing potent and highly selective neuroprotective therapies that have compelling preclinical pharmacologic profiles and for which clinical proof of concept can be obtained rapidly in order to address significant unmet patient needs.
IPO in 2017 (TK:MRSN)
Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary antibody drug conjugate (ADC) platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. The company’s lead product candidate, XMT1522, is in Phase I clinical trials and the second product candidate, XMT1536, will be entering clinical trials in early 2018. In addition, multiple partners are advancing their pipeline of ADCs using the Mersana platform.
Metabomed is a drug discovery company in the field of cancer metabolism. The company is developing a proprietary target identification platform based on computational biology, genomics and metabolomics. The platform identifies metabolic gene targets that arise uniquely in cancers and trigger synthetic lethality in order to develop small molecules that specifically target cancer cells’ metabolism to halt their growth.
MISSION is discovering and developing first-in-class therapeutics that inhibit disease associated deubiquitinylase enzymes (DUBs) involved in serious diseases including mitochondrial diseases, neurodegeneration, inflammation, and cancer. The company has built a proprietary world-leading DUB platform that is generating a rich pipeline of potent and selective small molecule drugs, with clinical and commercial potential. Several programs are advancing towards clinical development.
San Francisco, CA
Mitokinin is developing small molecule therapeutics targeting PINK1, a master regulator of mitochondrial quality control genetically linked to Parkinson’s disease. By selectively amplifying active-form PINK1 activity, Mitokinin believes it can address the cellular pathologies underlying Parkinson’s disease and ultimately slow or halt the progression of the disease.
Morphic Therapeutic is engaged in the discovery and development of a new generation of oral integrin drugs. Based on research conducted in the laboratory of the company’s founding scientist, Tim Springer, Morphic is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders and immune-oncology.
Ann Arbor, MI
NeuMoDx is developing a next generation testing platform for the in vitro molecular diagnostic (MDx) market. The product vision is to create a walk-away bench-top system that combines sensitivity, high speed (time to first result and throughput), low cost, and random access, in an “open” architecture that can support both IVDs and Lab Developed Tests (LDTs).
IPO in 2018 (TK: STIM)
Focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses, Neuronetics is the first company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. Neuronetics is the leader in the development of NeuroStar TMS Therapy (transcranial magnetic stimulation), a non-invasive form of neuromodulation.
IPO in 2019 (TK: NXTC)
NextCure is discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases, building upon the work of its scientific founder, Dr. Lieping Chen. The company is focused on understanding novel tumor specific interactions and mechanisms of immune regulation at work in the tumor microenvironment to build a proprietary pipeline for mediating sustained immunity and improved outcomes for cancer patients.
Nimbus harnesses the power of computational chemistry to design breakthroughs for the treatment of substantial and underserved human diseases. The company’s focus on metabolic diseases, cancer and immune-inflammatory disorders reflects the mechanistic relationship between these disorders, and Nimbus’ ability to rapidly tackle well validated targets as well as those that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry, resulting in medicines with high potency, selectivity and other desirable drug-like properties. The company’s advanced programs include ACC, IRAK4, Tyk2, and STING. ACC program was acquired by Gilead.
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glycoimmune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis.
New York, NY
Petra Pharma is a drug development company focused on novel enzyme targets that play a central role in a variety of important cellular processes, including cell division, growth, trafficking, and signaling. Petra Pharma will develop novel small molecules for the treatment of cancer and metabolic diseases to target these cellular processes in order to therapeutically impact human health.
RefleXion Medical is developing the first biologically guided radiation therapy system for treating solid tumors throughout the body. By uniquely leveraging Positron Emission Tomography (PET), RefleXion's patented technology uses signals that are continuously emitted from the tumor itself to guide the treatment beam.
IPO in 2017 (TK: RTHM)
Rhythm is a biopharmaceutical company developing peptide therapeutics that address unmet needs in metabolic diseases: RM-493, a small-peptide melanocortin-4 receptor (MC4R) agonist, for the treatment of obesity and diabetes; and RM-131, a small-peptide ghrelin agonist, for the treatment of diabetic gastroparesis. RM-131 was acquired by Allergan.
South San Francisco
Second Genome has built a novel microbiome technology platform, resulting in a pipeline of drug discovery programs, including a number of microbiome-derived proteins, peptides and metabolites, with applications across gastrointestinal disease, immuno-oncology, inflammation and metabolic diseases. Second Genome leverages its dynamic digital microbiome database and AI to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries.
New Haven, CT
Simcha Therapeutics is an early stage biopharmaceutical company with a focus on developing next generation cytokine immunotherapies to trigger the immune system to fight disease, particularly cancers. The company was incorporated in 2018 and is based in New Haven, Connecticut.
Storm Therapeutics is the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics. The company was spun out of Cambridge University, translating the ground-breaking research of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into first-in-class drugs in oncology and other diseases.
Ann Arbor, MI
Strata Oncology is a precision oncology company aiming to enable large-scale molecularly-informed clinical cancer research. To that end, the company has developed an end-to-end technology platform for sequencing tumors from patients across a network of large health systems and streamlining their enrollment in mutation-matched clinical trials of Strata’s Pharma partners.
Merged with MIRNA in 2017 (TK: SYBX)
Synlogic engineers Synthetic Biotic medicines, a new class of treatments generated using synthetic biology to re-engineer beneficial, probiotic bacteria. Synthetic Biotic medicines are designed to correct disease-causing metabolic dysregulation or deliver combinations of therapeutic factors with the potential to treat a wide range of diseases.
San Franscisco, CA
System1 employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases for which current discovery techniques have proved least successful. System1 combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. These “deep phenotypes” are exploited to identify novel therapeutic targets and drug treatments.
FKA - RaNa; IPO in 2018 (TK: TBIO)
Translate Bio is developing a new class of therapeutics made of messenger RNA (mRNA), designed to enable in vivo production of intracellular, membrane-associated and secreted proteins. Delivering mRNAs enables a patient's own cells to produce the proteins needed to treat or prevent diseases that cannot be addressed with current technologies.
TRex Bio is a stealth mode, discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases. TRex aims to achieve this vision via functional manipulation of Tregs and other immune cells in a tissue-specific and disease-specific fashion.
Yumanity Therapeutics proprietary platforms have identified previously unknown disease targets that when modulated can correct the cellular toxicities created by misfolded proteins. Beyond advancing the lead program that corrects toxicity associated with α-synuclein, a protein linked to Parkinson’s disease, the company is also identifying compounds for Alzheimer’s disease and ALS.
|Former Portfolio Companies|
Acquired by Deerfield Management
San Francisco, CA
Ablexis’ AlivaMab™ Mouse technology, a world-class transgenic mouse platform, is being developed to provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies to treat human diseases. Ablexis will commercialize the AlivaMab™ Mouse platform through creative partnering strategies.
IPO in 2014 (TK: AQXP)
Aquinox is developing novel small molecule therapeutics for the treatment of cancer and inflammatory disease. The primary focus is anti-inflammatory product candidates targeting SH2-containing inositol 5'-phosphatase (known as SHIP1), which plays an important role in the PI3K cellular signaling pathway in immune cells. Rosiptor, (AQX-1125), Aquinox’s lead candidate, is in a Phase 3 trial of interstitial cystitis / bladder pain syndrome (IC/BPS).
Out of Business
Aureon uses systems pathology to develop predictive clinical tests for cancer care, as well as to enable bio-pharmaceutical research and development. Their technology predicts individual clinical outcomes by interrogating and analyzing tissue, to provide the first comprehensive and fully integrated view of the disease process - a systems pathology view. In 2008, Aureon successfully launched their Px+ prostate biopsy test, which has already seen very rapid uptake in the market.
Acquired by Eli Lilly
Avid Radiopharmaceuticals, Inc. is a product-focused molecular imaging company that is a pioneer in developing radiopharmaceuticals for imaging disease pathology. The company’s beta-amyloid imaging agent for Alzheimer’s disease, Amyvid, was approved in 2012 and being commercialized. The Avid team is also developing novel agents targeted to image pathology in dementia with Lewy bodies, Parkinson’s disease, and has recently started a research project in diabetes mellitus.
Out of Business
Palo Alto, CA
Aviir is developing cutting-edge, convenient molecular diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology applies a deep understanding of disease marker proteins and advanced biostatistics to build prognostic profiles for atherosclerosis and is also aiming to develop a prognostic test for insulin resistance in the future.
IPO in 2011 (TK: CLVS)
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents. Clovis intends to target development programs at specific subsets of cancer populations, and will simultaneously develop diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.
DIR Technologies is a developer and manufacturer of inspection systems for the pharmaceutical and nutriceutical markets. The company has developed a suite of products that leverage thermal imaging, computer vision, and machine learning to provide in-line inspection of various manufacturing processes, such as induction sealing integrity and tablet/capsule bottle filling.
Acquired by Fluidigm
DVS Sciences Inc. is an analytical equipment and reagents development company that produces and markets the CyTOF® , a high throughput mass cytometer for individual cell analysis based on a novel elemental mass-spectrometry detection technology, and the MAXPAR® system of novel reagents related to massively multi-parametric assays.
Restart Following Bankruptcy
Foster City, CA
Entelos develops computer-based disease-simulation models, called PhysioLabs that enable in-silico drug discovery and development. Each PhysioLab platform provides a framework for integrating data (e.g., genomic, proteomic, physiologic, environmental) in the context of a disease or therapeutic area, focusing on understanding and determining clinical responses to potential treatment.
Acquired by Genstar Capital
Evolution Benefits (EB) offers innovative, integrated products for the employee benefits market. Their Benny™ prepaid benefits card acts as a comprehensive tool for managing the front and back-end functions involved in executing employee benefit programs. EB’s products make benefits programs easier for consumers to use, while at the same time reduce administrative burden to benefit managers.
IPO in 2014 (TK: FLXN)
Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA, a type of degenerative arthritis.
IPO in 2005 (TK: GHDX)
Redwood City, CA
Genomic Health is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, they launched their first test under the brand name Oncotype DX® for early stage breast cancer.
Acquired by Becton Dickinson
Ann Arbor, MI
HandyLab develops and manufactures small, low-cost nucleic acid and protein-based analysis systems based on its patented and proprietary microfluidic, miniaturized real time PCR, and nucleic acid extraction technologies. The company's lead product, Jaguar, combines rapid nucleic acid sample preparation with microfluidic PCR for nucleic acid detection.
Acquired by WuXi
HD Biosciences (HDB) is a Shanghai China based clinical research organization (CRO) that provides drug discovery contract research services, with an emphasis on high value biology screening. The company has developed comprehensive technology platforms and expertise around drug discovery assays, assay development, high throughput drug screening, and hit-to-lead biology. HD Biosciences customers include Pfizer and several other large pharmaceutical companies.
Acquired by Medstreaming
M2S is a pioneer and leader in imaging and data management technology. They were the first to develop and market 3-D imaging technology to vascular surgeons. Their Preview product is still the market leader in this field. In 2006, the company expanded into providing core lab services for clinical trials and customized data registries for physicians, hospitals, medical centers, and clinical researchers.
IPO in 2016 (TK: MRUS)
Utrecht, The Netherlands
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.
Out of Business
NeuroTherapeutics Pharma, Inc. (NTP) is focused on developing therapies for diseases associated with central nervous system hyper-excitability. The company is working with novel mechanisms that will generate first-in-class therapeutics, thereby changing the standard of care for patients suffering from epilepsy, neuropathic and acute pain, and other disorders of the nervous system.
NexImmune is developing novel immune-therapeutics based on the proprietary Artificial IMmune (AIMTM) technology. The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cells (APC). NexImmune is applying the AIM technology to the development of immune-therapies for a variety of cancers and other diseases.
Technology merged with another company
South San Francisco, CA
Nodality, Inc. is an emerging biotechnology company focused on patient-specific classification of disease. Nodality's technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The technology can address many aspects of drug development with a primary focus on acute myeloblastic leukemia (AML) and chronic lymphocytic leukemia (CLL).
IPO in 2015 (TK: NVCR)
Therapeutic oncology device that delivers Tumor Treating Fields (TTFields) to tumor sites through the skin. The TTfields are low intensity, alternating electric fields that cause physical disruption of dividing (cancerous) cells, but leave normal cells largely unaffected. The company’s lead program in brain cancer (GBM) has received US regulatory approval. Additional studies are also planned in other major cancer indications.
Out of business
Quartet is an early-stage biopharmaceutical company developing drugs against a novel pain target, Tetrahydrobiopterin (BH4), an essential co-factor in the production of certain neurotransmitters.
Acquired by Covidien
superDimension has developed the inReach™ system in answer to one of the most critical needs in the field of pulmonology: minimally invasive access to peripheral lung locations. The inReach™ system enables accurate and minimally invasive navigation anywhere in the lungs in real time and on a 3D CT roadmap, increasing both the success rate and applicability of diagnostic bronchoscopy.
Merged with Tracelink
Provider of pharmaceutical supply chain security solutions to pharmaceutical companies and their trading partners seeking to enhance product integrity and supply chain efficiency. The company has developed technology to track and store the movement of drugs throughout the pharmaceutical supply chain using radio frequency identification to protect the drug supply from counterfeiters.
Out of business
TetraLogic is a biopharmaceutical company developing novel, targeted drugs to treat cancer. The company’s Smac-mimetic candidates regulate the apoptosis (programmed cell death) pathway by unblocking the pathway to kill cancer cells. IPO 2013. Assets sold to Medivir in Dec 2016.
Acquired by Pfizer
Therachon is a clinical-stage global biotechnology company focused on developing medicines for rare diseases with significant unmet need. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of disproportionate short stature in humans.
Acquired by Sucampo
Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. The first spin-out company from Cydan Development, Inc., an orphan-drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, Vtesse is working collaboratively with the NIH to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs.
Acquired by Novartis
Ziarco is a clinical stage biotechnology company developing innovative therapeutics targeting inflammatory skin diseases. The company’s lead compounds are ZPL-389, an oral histamine H4 receptor antagonist entering Phase 2 studies for atopic dermatitis and ZPL-521, a cPLA-2 inhibitor being advanced for psoriasis.